Aripra15 mg

Aripra 15 mg is indicated for- Schizophrenia Schizoaffective disorder Acute manic and mixed episodes associated with Bipolar I Disorder Maintaining efficacy in patients with Bipolar I Disorder who are stabilized

Atypical neuroleptic drugs

Aripra 15 mg is an atypical antipsychotic that has both dopamine and serotonin receptors activity. It is a partial agonist of dopamine D2 receptors that relieves the symptoms of schizophrenia. It is characterized as a dopamine system stabilizer. It is a potent partial agonist at serotonin 5-HT1A receptors and antagonist at 5-HT2A receptors. This is associated with improvement of depressive, cognitive and negative symptoms.

For Schizophrenia: 10 to 15 mg, once daily, without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.For Bipolar mania: 30 mg, once daily, without regard to food.

For Schizophrenia: 10 to 15 mg, once daily, without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.For Bipolar mania: 30 mg, once daily, without regard to food.

Caution should be exercised when aripipazole is taken in combination with other centrally acting drugs and alcohol. Carbamazepine could cause an increase in Aripra 15 mg clearance and lower blood levels. Ketoconazole, quinidine, fluoxetine or paroxetine can inhibit Aripra 15 mg elimination and cause increased blood levels.

Aripra 15 mg is contraindicated in patients who are hypersensitive to it or to any component of this product.

Headache, constipation, asthenia, nausea, dyspepsia, vomiting, coughing, abdominal pain.

Aripra 15 mg should not be used in pregnancy as no human trial is performed. Patients should be advised not to breast feed an infant if they are taking Aripra 15 mg.

Aripra 15 mg may be associated with orthostatic hypotension (orthostatic lightheadedness).Aripra 15 mg should be used with caution in patients with known cardiovascular disease (myocardial infarction or ischaemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications).Seizures occurred in Aripra 15 mg-treated patients. As with other antipsychotic drugs, Aripra 15 mg should be used cautiously in patients with Alzheimer's dementia.Aripra 15 mg is not approved for the treatment of patients with dementia-related psychosis.

Aripra 15 mg at doses up to 1080 mg causes no fatalities. The signs and symptoms observed with Aripra 15 mg overdose included nausea, vomiting, asthenia, diarrhea, and somnolence.

Atypical neuroleptic drugs

Aripra 15 mg is an atypical antipsychotic that has both dopamine and serotonin receptors activity. It is a partial agonist of dopamine D2 receptors that relieves the symptoms of schizophrenia. It is characterized as a dopamine system stabilizer. It is a potent partial agonist at serotonin 5-HT1A receptors and antagonist at 5-HT2A receptors. This is associated with improvement of depressive, cognitive and negative symptoms.

Aripra 15 mg should not be used in pregnancy as no human trial is performed. Patients should be advised not to breast feed an infant if they are taking Aripra 15 mg.